United Therapeutics

UTHR83

High Quality

$345.63arrow_drop_down1.25%-$4.38

High Quality

UTHR83

$345.63

arrow_drop_down1.25%-$4.38

High Quality

Performance History

Key Stats
Open	$349.76
Prev. Close	$350.01
EPS	21.77
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

	LOW	HIGH
Day Range	345.32	351.64
52 Week Range	208.62	366.07

Ratios







EPS	21.77

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About United Therapeutics (UTHR)

United Therapeutics Corp (UTHR) is a biotechnology company that focuses on the development and commercialization of innovative therapies for patients with chronic and life-threatening conditions. With a strong commitment to improving the lives of patients, United Therapeutics has become a leader in the field of pulmonary arterial hypertension (PAH) and other orphan diseases. The company's portfolio includes approved products like Remodulin, Tyvaso, and Orenitram, as well as a pipeline of promising candidates in various stages of clinical development.

One of the key factors that sets United Therapeutics apart from its competitors is its dedication to research and innovation. The company invests heavily in R&D, with the goal of discovering and developing breakthrough therapies that address unmet medical needs. This commitment to scientific excellence has earned United Therapeutics a solid reputation in the industry and has helped drive its growth and success.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Headquarters: Silver Spring
Employees: 985
Exchange: NASDAQ

Keep an eye on United Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the market capitalization of United Therapeutics (UTHR)?

United Therapeutics (UTHR) has a market capitalization of $15.58B. The average daily trading volume is 362.25K, indicating the stock's liquidity and investor engagement.

help

What is United Therapeutics's (UTHR) price per share?

The current price per share for United Therapeutics (UTHR) is $345.63. The stock has seen a price change of -$4.38 recently, indicating a -1.25% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for United Therapeutics (UTHR)?

For United Therapeutics (UTHR), the 52-week high is $366.08, which is 5.92% from the current price. The 52-week low is $208.62, the current price is 65.67% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is United Therapeutics (UTHR) a growth stock?

United Therapeutics (UTHR) has shown an average price growth of 0.41% over the past three years. It has received a score of 65 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying United Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is United Therapeutics (UTHR) stock price performance year to date (YTD)?

As of the latest data, United Therapeutics (UTHR) has a year-to-date price change of 52.03%. Over the past month, the stock has experienced a price change of 7.35%. Over the last three months, the change has been 25.05%. Over the past six months, the figure is 45.85%. Looking at a longer horizon, the five-year price change stands at 329.67%.

help

Is United Therapeutics (UTHR) a profitable company?

United Therapeutics (UTHR) has a net income of $984.8M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 88.94% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 44.75% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.33B, with a revenue growth rate of 20.2%, providing insight into the company's sales performance and growth. The gross profit is $2.07B. Operating income is noted at $1.18B. Furthermore, the EBITDA is $1.52B.